Abstract
The uPA system mainly comprises the urokinase-type plasminogen activator uPA, the cell-surface receptor uPA receptor and the inhibitor PAI-1. Its clinical and prognostic impact especially in breast cancer is well investigated. In this short report, we summarize the published data describing expression of uPA, PAI-1 and uPA receptor and their relevance to clinical and survival data in sarcomas underlining their impact as tumor biomarkers in this tumor type as well.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Biomarkers, Tumor / blood
-
Biomarkers, Tumor / genetics
-
Humans
-
Plasminogen Activator Inhibitor 1 / blood*
-
Plasminogen Activator Inhibitor 1 / genetics
-
Plasminogen Activator Inhibitor 2 / blood*
-
Plasminogen Activator Inhibitor 2 / genetics
-
Receptors, Urokinase Plasminogen Activator / blood*
-
Receptors, Urokinase Plasminogen Activator / genetics
-
Sarcoma / blood*
-
Sarcoma / enzymology
-
Sarcoma / genetics
-
Urokinase-Type Plasminogen Activator / blood
-
Urokinase-Type Plasminogen Activator / genetics*
Substances
-
Biomarkers, Tumor
-
Plasminogen Activator Inhibitor 1
-
Plasminogen Activator Inhibitor 2
-
Receptors, Urokinase Plasminogen Activator
-
Urokinase-Type Plasminogen Activator